

**Scientific Spring Meeting**  
**Friday April 7, 2017**

**Dutch Society for Clinical Pharmacology and Biopharmacy**  
**Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie**

**PROGRAMME of the SCIENTIFIC MEETING**  
**Friday April 7, 2017**  
**Auditorium Radboudumc Nijmegen**

---

**SCIENTIFIC MEETING OF THE DUTCH SOCIETY FOR CLINICAL PHARMACOLOGY AND BIOPHARMACY (NVKFB)**

09.00 h **Welcome & coffee**

**ORAL PRESENTATIONS**

- 09.30 h *A. Abdulla, N.G.M. Hunfeld, A. Dijkstra, S. Duran, J.W. Mouton, D.A.M.P.J. Gommers, T. van Gelder, B.C.P. Koch* (Rotterdam): Beta-lactam and fluoroquinolone pharmacokinetic/pharmacodynamic target attainment in critically ill patients (EXPAT)
- 09.45 h *P.C.D. Bank, J.J. Swen, R.D. Schaap, D.B. Klootwijk, R.F. Baak – Pablo, H.J. Guchelaar* (Leiden): Implementation of pharmacogenomics into primary care
- 10.00 h *E. Beers, A.M. Caro, A.S. Vos, H.C.P.M. van Weert* (Amsterdam): Deprescribing in cancer patients with a limited life expectancy in primary care: a retrospective longitudinal study
- 10.15 h *P.A.J.G. De Cock, H. Mulla, S. Desmet, F. De Somer, B.C. McWhinney, J.P.J. Ungerer, A. Moerman, S. Commeyne, J. Vande Walle, K. Francois, J.G.C. van Hasselt, P. De Paepe* (Gent): Optimizing cefazolin dosing in children undergoing cardiac surgery with cardiopulmonary bypass using a model-based dosing regimen
- 10.30 h *L.G. Franken, A.D. Masman, M. van Dijk, F.P.M. Baar, D. Tibboel, B.C.P. Koch, T. van Gelder, R.A.A. Mathot, B.C.M de Winter* (Rotterdam): A pharmacodynamic model of midazol-induced sedation in terminally ill patients

- 10.45 h *H. Maagdenberg, M.B. Bierings, A. de Boer, A.H. Maitland-van der Zee on behalf of the CAPS collaborators (Utrecht): The children anticoagulation and pharmacogenetics study (CAPS): developing a dosing algorithm for acenocoumarol for paediatric patients*
- 11.00 h **Coffee and Tea Break**
- 11.15 h *S. Schalkwijk, A.O. Buaben, A.P. Colbers, D.M. Burger, R. Greupink, F.G.M. Russel (Nijmegen): Dosing for two: placental transfer and fetal darunavir exposure*
- 11.30 h *R.B. Verheijen, T.T. van Duijl, M.M. van den Heuvel, J.H. Beijnen, J.H.M. Schellens, D. van den Broek, N. Steeghs, A.D.R. Huitema (Amsterdam): Monitoring of circulating tumor DNA in non-small cell lung cancer patients treated with EGFR-inhibitors*
- 11.45 h **GENERAL MEETING of the ‘NVKFB’**
- 12.30 h **LUNCH and POSTER SESSION**
1. *R.A. Wijma, B.C.P. Koch, T. van Gelder, J.W. Mouton (Rotterdam): An evaluation of the effectivity of the current treatment of uncomplicated urinary tract infections with fosfomycin based on urinary concentrations in healthy volunteers*
  2. *C. van der Heijden, M. Duizer, B. Veldman, T. Sprong, H. Fleuren, A. Dofferhoff, C. Kramers (Nijmegen): Intravenous flucloxacillin treatment is associated with hypokalemia in hospitalized patients*
  3. *L. Dossche, R. Michelet, P. De Bruyne, J. Van Bocxlaer, A. Vermeulen, J. Vande Walle (Gent): Bioequivalence in adults does not mean bioequivalence in children*
  4. *Z.Z.R.M. Weerts, D. Keszthelyi, H.W. Frijlink, J.R.B.J. Brouwers, L. Vork, D.M.A.E. Jonkers, A.A.M. Mascle (Maastricht): A randomized, double-blind, crossover study on pharmacokinetics of peppermint oil in healthy volunteers: enteric-coating versus colon-targeted-delivery*
  5. *R. Admiraal, S. Nierkens, M.A. de Witte, E.J. Petersen, G. Fleurke, L. Verrest, S.V. Belitser, R.G.M. Bredius, R.A.P. Raymakers, C.A.J. Knibbe, M.C. Minnema, C. van Kesteren, J. Kuball, J.J. Boelens (Utrecht): Optimising anti-thymocyte globulin exposure in hematopoietic cell transplantation: a retrospective pharmacokinetic-pharmacodynamic analysis*
  6. *S.T. de Vries, M.J.M. van der Sar, P. Denig, P.G.M. Mol on behalf of SCOPE work package (Groningen): Communication on safety of medicines in Europe: current practices and general practitioners’ awareness and preferences*

7. *A.E. Kip, S. Blesson, F. Alves, R. Kimutai, P. Menza, B. Mengesha, J.H.M. Schellens, J.H. Beijnen, A. Hailu, E. Diro, T.P.C. Dorlo* (Amsterdam): Pharmacokinetics of simultaneously administered antileishmanial and antiretroviral drugs in visceral leishmaniasis patients co-infected with HIV in Ethiopia
8. *J.A. Dijkstra, T. van der Laan, O.W. Akkerman, M.S. Bolhuis, W.C.M. de Lange, J.G.W. Kosterink, T.S. van der Werf, J.W.C. Alffenaar, D. van Soolingen* (Groningen): Comparison of the in vitro activity of amikacin and kanamycin against *Mycobacterium tuberculosis* and target attainment
9. *A.H. Neerincx, S.J.H. Vijverberg, P. Brinkman, A.D. Kraneveld, U. Potocnik, M. Pino-Yanes, O. Sardon Prado, M. Kabesch, A.H. Maitland-van der Zee* (Amsterdam): A systems pharmacology approach to difficult-to-treat pediatric asthma: design of the SysPharmPediA study
10. *M.T.J. van Bussel, D. Pluim, B. Milojkovic-Kerklaan, D. van den Broek, J.H. Beijnen, W. Boogerd, J.H.M. Schellens, E. Le Rhun, D. Brandsma* (Amsterdam): Circulating tumor cells and circulating tumor DNA analysis in cerebrospinal fluid in melanoma patients with suspected leptomeningeal metastasis
11. *S.E. Berends, G. D'Haens, J.C.J. van Selm, A.S. Strik, M. Löwenberg, C.Y. Ponsioen, R.A.A. Mathôt* (Amsterdam): Factors influencing clearance of adalimumab in patients with Crohn's disease: a population pharmacokinetic study
12. *A. Colbers, S. Schalkwijk, D. Konopnicki, A. Gingelmaier, J. Lambert, M. van der Ende, J. Moltó, D. Burger on behalf of the PANNA network* (Nijmegen): Substantially lower rilpivirine plasma concentrations during pregnancy
13. *D.J. Brinkman, J. Tichelaar, M. Okorie, L. Bissell, T. Christiaens, R. Likic, R. Maciulaitis, J. Costa, E. Sanz, B.I. Tamba, S.R. Maxwell, M.C. Richir, M.A. van Agtmael* (Amsterdam): Pharmacology and therapeutics education in EU needs harmonisation and modernisation: a cross-sectional survey among 185 medical schools in 27 countries
14. *M.B.S. Crombag, J.G.C. van Doremalen, A.H.M. de Vries Schultink, J.H.M. Schellens, J.H. Beijnen, A.D.R. Huitema* (Amsterdam): Hematological toxicity in older patients treated with docetaxel or docetaxel-containing regimens
15. *M.B.S. Crombag, J.G.C. van Doremalen, J.H.M. Schellens, J.H. Beijnen, N. Steeghs, A.D.R. Huitema* (Amsterdam): Therapeutic drug monitoring of tyrosine kinase inhibitors in older patients
16. *S. Völler, R.B. Flint, L.M. Stolk, P.L.J.M. Degraeuwe, S.H.P. Simons, D.M. Burger, C.A.J. Knibbe* (Leiden): A population pharmacokinetic model for phenobarbital in term and preterm neonates

17. *P.A.J.G. De Cock, M. Wollaert, S. Desmet, B. McWhinney, A. de Jaeger, J. Vande Walle, P. De Paepe* (Gent): Observational study on target attainment and protein binding of teicoplanin in critically ill children
18. *P. De Bruyne, J. Vande Walle, on behalf of the SAFE-PEDRUG consortium (IWT SBO-130033)* (Gent): The safe-pedrug initiative: a new approach for efficient and ethical paediatric drug research
19. *N. Farzan, S.J. Vijverberg, J.A. Raaijmakers, A.H. Maitland-van der Zee on behalf of the PiCA consortium* (Utrecht): 17q21 gene variation increases the risk of exacerbations in asthmatic children treated with inhaled corticosteroids: a meta-analysis in the multi-ethnic PiCA consortium
20. *B.C. Witjes, A.S. Zandvliet, J.A. Dijkstra, W.A. Kors, F.C. Abbink, S.E. Smetsers, E.L. Swart, F. Sombogaard, A.J. Wilhelm* (Amsterdam): Voriconazole dosing strategies in young children: challenges and recommendations
21. *O. van Katwijk, S. Croes, A. Verbon, D. Posthouwer, M.B. Haeseker, L.M.L. Stolk* (Maastricht): Augmented vancomycin clearance in neutropenic patients: assessing predictors and adequate treatment
22. *B.D. van Groen, E. van de Steeg, M.M.H. van Lipzig, M.G. Mooij, H.M. Wortelboer, D. Tibboel, W.H. Vaes, S.N. de Wildt* (Rotterdam): Maturation of human hepatic membrane transporter proteins in the first four months of life
23. *B.D. van Groen, M.G. Mooij, E. van Duijn, C.A. Knibbe, K. Allegaert, A.D. Windhorst, J. van Rosmalen, N.H. Hendrikse, D. Tibboel, W.H.J. Vaes, S.N. de Wildt* (Rotterdam): Pediatric microdose study of [<sup>14</sup>C]midazolam to study the ontogeny of CYP3A mediated drug metabolism
24. *Y.A. Bijleveld, T.R. de Haan, R.A.A. Mathôt* (Amsterdam): Population pharmacokinetics of amoxicillin and gentamicin in term neonates undergoing moderate hypothermia
25. *I. Önsesveren, R. van Westrhenen, A.I. Wierdsma, L. de Haan, C.L. Mulder* (Rotterdam): Penfluridol (oral long acting antipsychotic agent) as compared to second-generation antipsychotics: an ongoing randomized controlled trial on effectiveness
26. *T. Preijers, H.C.A.M. Hazendonk, R. Liesner, P. Chowdary, M.H.E. Driessens, D. Hart, D. Keeling, B.A.P. Laros-van Gorkom, F.J.M. van der Meer, K. Meijer, K. Fijnvandraat, F.W.G. Leebeek, P.W. Collins, M.H. Cnossen, R.A.A. Mathôt for the "OPTI-CLOT" study group* (Amsterdam): Population pharmacokinetic analysis of perioperative factor IX dosing in hemophilia B

27. *A.N. Bindraban, J. Rolvink, F.A. Berger, P.M.L.A. van den Bemt, R.T.M. van der Hoeven, A.K. Mantel-Teeuwisse, M.L. Becker* (Haarlem): Development of a model to predict QTc prolongation in patients who use one or more QT-prolonging drugs
28. *J.J.M. Rood, A. Jamalpoor, M.J. van Haren, M.J. Janssen, J.H.M. Schellens, J.H. Beijnen, R.W. Sparidans* (Utrecht): Extrahepatic metabolism of the targeted covalent inhibitor ibrutinib through the glutathione cycle
29. *A. Raaijmakers, Z.Y. Zhang, E. Levchenko, S. Simons, B. van den Heuvel, L. Jacobs, J.A. Staessen, K. Allegaert* (Leuven): Perinatal drug exposure in extreme low birth weight infants and subsequent renal outcome in childhood: a safety study is feasible
30. *E.M.J. van Brummelen, A. de Boer, J.H. Beijnen, J.H.M. Schellens* (Amsterdam): *BRAF* mutations as predictive biomarker for response to anti-EGFR monoclonal antibodies: proposal for an update of the drug label of panitumumab and cetuximab
31. *F. Besemer, C. Kramers, K. Brinkman, A.R.M.M. Hermus, A.E. van Herwaarden, D.M. Burger* (Nijmegen): Prevalence of hypothalamic-pituitary-adrenal axis suppression by inhalation or nasal corticosteroids in HIV-infected patients
32. *K. Meesters, R. Mauel, J. Vande Walle, P. De Bruyne* (Brussel): Systemic fluoroquinolone use in hospitalized children in Belgium, results of a multicenter retrospective drug utilization study
33. *L.C. Martial, R.E. Aarnoutse, M.F. Schreuder, S.S. Henriët, R.J.M. Brüggemann, M.A. Joore* (Nijmegen): Cost evaluation of dried blood spot home sampling as compared to conventional sampling for therapeutic drug monitoring in children
34. *L.M. Henricks, E. Kienhuis, F.M. de Man, A.A.M. van der Veldt, P. Hamberg, A.B.P. van Kuilenburg, C.A.T.C. Lunenburg, H-J. Guchelaar, J.H.M. Schellens, R.H.J. Mathijssen* (Amsterdam): Safe treatment of homozygous or compound heterozygous *DPYD* variant allele carriers with low dose fluoropyrimidines is feasible
35. *L. van Andel, Z. Zhang, S. Lu, V. Kansra, S. Agarwal, L. Hughes, M.M. Tibben, A. Gebretensae, L. Lucas, M.J.X. Hillebrand, H. Rosing, J.H.M. Schellens, J. H. Beijnen* (Amsterdam): Human mass balance and metabolite profiling of <sup>14</sup>C-niraparib in patients with cancer
36. *R.A. Wijma, S. Bahmany, E.B. Wilms, T. van Gelder, J.W. Mouton, B.C.P. Koch* (Rotterdam): A simple and fast LC-MS/MS method for the quantification of fosfomycin in urine and plasma using one sample preparation method and HILIC chromatography
37. *J.M. Bos, S. Natsch, P.M.L.A. van den Bemt, J.L.W. Pot, J.E. Nagtegaal, A. Wieringa, G.J. van der Wilt, P.A.G.M. De Smet, C. Kramers* (Nijmegen): A multifaceted intervention to improve guideline adherence among prescribing physicians at surgical wards

38. *S.C. Bergheanu, K.M.S. Kanhai, Y.L. Wagenaar, J.A. Nij Bijvank, E.S. Klaassen, K.S. Lim, A. Petzold, A. Verma, R. van Rijn, G.J. Groeneveld* (Leiden): Effects of a single-dose fampridine on internuclear ophthalmoplegia (INO) severity in patients with multiple sclerosis (MS)
39. *C. Bastida, D. Soy, A.H.M. de Vries Schultink, V. Ruíz, R. Sanmartí, M. Pascal, J. Yagiüe, A.D.R. Huitema* (Amsterdam): Population pharmacokinetic analysis of intravenous tocilizumab in rheumatoid arthritis patients
40. *M.S. Bolhuis, E. Van Kampenhout, J.W.C. Alffenaar, J.G.W. Kosterink, T.S. van der Werf, O.W. Akkerman* (Groningen): Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a MDR-TB patient
41. *P. Mian, A.J. Valkenburg, K.M. Allegaert, B.C.P. Koch, C.V. Breatnach, C.A.J. Knibbe, D. Tibboel, E.H.J. Krekels* (Rotterdam): Population pharmacokinetic modelling of paracetamol after cardiac surgery in children with and without Down syndrome
42. *J.M. Janssen, C.M. Zwaan, J.H.M. Schellens, J.H. Beijnen, A.D.R. Huitema* (Amsterdam): Clinical trial simulations in paediatric oncology: a feasibility study with bosutinib in paediatric CML
43. *M. Herbrink, N. de Vries, H. Rosing, A.D.R. Huitema, B. Nuijen, J.H.M. Schellens, J.H. Beijnen* (Amsterdam): Development and validation of a liquid chromatography-tandem mass spectrometry assay for the therapeutic drug monitoring of 8 novel anticancer drugs
44. *T. De Backer, C. Detremerie, M. Petrovic* (Gent): Treatment of hypertension in the frail elderly
45. *J.J. Geenen, G.M. Dackus, P.C. Schouten, S. Marchetti, H. van Tinteren, J.H. Beijnen, G.S. Sonke, S.C. Linn, J.H. Schellens* (Amsterdam): The REVIVAL study: olaparib and carboplatin as first line treatment in advanced BRCA mutated breast cancer
46. *L.M. Andrews, B.C.P. Koch, D.A. Hesselink, E.A. Cornelissen, S.N. de Wildt, T. van Gelder, K. Cransberg, B.C.M. de Winter* (Rotterdam): New population pharmacokinetic model that predicts the starting dose of tacrolimus following pediatric renal transplantation
47. *S.C. Goulooze, E.H.J. Krekels, S.J.G.M. Ahlers, M.A. Saleh, P.A.J. Väitalo, D. Tibboel, C.A.J. Knibbe* (Leiden): Repeated time-to-event modeling of rescue morphine during recovery from cardiac surgery

48. *M.L. Toren-Wielema, R.B. Veenhuizen, J.W. Kappelle, N.J.G.M. Veeger, E.N. van Roon* (Leeuwarden): Efficacy of a standardized oral vitamin D dosing regimen in somatic and psychogeriatric nursing home residents
49. *S. Cristea, A. Smits, A. Kulo, C.A.J. Knibbe, M. van Weissenbruch, E.H.J. Krekels, K. Allegaert* (Leiden): Amikacin pharmacokinetics to optimize dosing recommendations in neonates with perinatal asphyxia treated with hypothermia
50. *S.M. Kloosterboer, B.C.M. de Winter, T. van Gelder, B. Dierckx, B.C.P. Koch* (Rotterdam): Clinical validation of a Dried Blood Spot method for determination of risperidone, aripiprazole, pipamperone and their major metabolites
51. *S. Wassenaar, H.H. Bijma, B.J. Sibbles, A.J. Schneider, A.A. Aaldriks, B.C.N. van der Nagel, E.A.P. Steegers, B.C.P. Koch* (Rotterdam): Prevalence estimation of alcohol consumption by pregnant women using the new biomarker phosphatidylethanol (PEth)
52. *M. Roskam-Kwint, P. Bollen, A. Colbers, M. Duisenberg-van Essenberg, V. Harbers, D. Burger* (Nijmegen): Crushing of dolutegravir combination tablets increases dolutegravir exposure
53. *P.J. Glerum, Y. Yu, W. Yamada, M. Neely, M. Maliepaard, D. Burger, C. Neef* (Utrecht): Robustness of the conclusion of bioequivalence; a non-parametric comparison
54. *N. Boone, L. Lui, M. Romberg, L. Duijsens, H. van der Kuy, R. Janknegt, A. van Bodegraven* (Sittard): Transition study of biosimilar infliximab in patients with inflammatory bowel disease
55. *C. Mestres Gonzalvo, H.A.J.M. de Wit, B.P.C. van Oijen, D. Deben, K.P.G.M. Hurkens, W.J. Mulder, R. Janknegt, J.M.G.A. Schols, F.R. Verhey, B. Winkens, P.H.M. van der Kuy* (Sittard-Geleen): Prospective validation of an automated delirium prediction model
- 13.30 h *Prof. dr. A. de Boer: DOACS: what have we learned from post-marketing studies?*
- 13.50 h Lecture of the winner of the ‘NVKFB’-Thesis Award 2016
- 14.10 h Lecture of the winner of the ‘NVKFB’-TOP Publication Award 2016
- 14.25 h Lecture of the winner of the ‘NVKFB’-Education Award 2016



## ORAL PRESENTATIONS

- 14.45 h *R.E. Wasmann, R. ter Heine, D.M. Burger, C.A. Knibbe, R.J. Brüggemann* (Nijmegen): One size does not fit all: How to adjust the dose of anidulafungin in obesity
- 15.00 h *T.M. van der Zanden, M. de Hoog, J.D. Windster, S.N. de Wildt, I.H. van der Sijs* (Rotterdam): Reduction of calculation errors with the Dutch pediatric formulary's web-based paediatric dosing calculator
- 15.15 h *V.A. de Weger, A.D.R. Huitema, B. Nuijen, J.H. Beijnen, S. Pulleman, M. Mergui, J.H.M. Schellens, S. Marchetti* (Amsterdam): Phase I dose-finding studies with the oral docetaxel formulation ModraDoc006 co-administered with ritonavir (ModraDoc006/r)
- 15.30 h *A. Smits, P. Steven, M. Oyaert, N. Peersman, I. Spriet, V. Saegeman, K. Allegaert* (Leuven): Vancomycin protein binding in neonates and young infants
- 15.45 h** **Closure**
- 16.30 h** **Inaugural lecture prof. dr. S.N. de Wildt** (Aula Radboud University, Comeniuslaan 2, Nijmegen)